Painless Laser Therapy for Overactive Bladder

Inclusion Criteria: * The subject is female and at least 18 years of age at screening. * A score of \> 4 on the OAB-q short form for urgency. * The subject has an average urinary frequency of \> 10 voids per day. * Self-reported bladder symptoms for \> 3 months. * Self-reported failed conservative care. * The subject has discontinued all antimuscarinics for at least 2 weeks prior to screening. * The subject is ambulatory and able to use the toilet independently and without difficulty. * Negative pregnancy test in subjects of childbearing potential. * Subject attests in writing that she has not had unprotected intercourse within 3 weeks prior to study enrollment and agrees to have no intercourse until treatments conclude. * Subject Informed Consent obtained in writing in compliance with local regulations prior to enrollment into this study. * The subject (and caregiver, if applicable) is willing to participate in this study for at least 7 weeks. * The subject is otherwise in general good health with no other major medical conditions. Exclusion Criteria: * The subject has vaginal bleeding. * The subject has urinary or gastric retention or a neurogenic bladder. * The subject is not capable of completing study questionnaires or undergoing portions of the study. * The subject has been sexually assaulted. * The subject has an alcohol or drug addiction. * The subject has used isotretinoin (Accutane) within 6 months prior to study enrollment. * The subject has cancer. * The subject has used Botox® in the bladder or pelvic floor muscles within 12 months prior to study enrollment. * The subject currently has a urinary tract infection or vaginal infection. * The subject is using Interstim® or Bion®. * Current use of TENS in pelvic region, back or legs. * The subject is pregnant or lactating, or is of childbearing potential unless she is surgically sterile or she and/or her partner are using a medically acceptable method of birth control. * Any use of light-activated drugs (photodynamic therapy) or heat sensitive medications within 30 days of first treatment. * The subject has used an investigational drug/device therapy or participated in any clinical investigation involving or impacting gynecologic, urinary, or renal function within 4 weeks prior to study enrollment. * The subject is otherwise determined, based on the opinion of the Investigator, to be an unsuitable candidate for enrollment in this study.